FUSN — Fusion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $1.83bn
- $1.67bn
- $2.07m
Fusion Pharma jumps on acquiring prostate cancer drug candidate
U.S. STOCKS ON THE MOVE-Nvidia, Peabody Energy, Zoetis
U.S. STOCKS ON THE MOVE-Coca-Cola, Ford, Fusion Pharma
Fusion Pharma rises on acquiring prostate cancer candidate
Brief: Fusion Pharmaceuticals To Acquire Phase 2 Program For 225Ac-Psma I&T, A Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Brief: Fusion Pharmaceuticals Reports Progress, Provides Corporate Highlights
Brief: Fusion Pharmaceuticals And Bwxt Medical Announce Actinium-225 Partnership To Scale Supply For Developing Targeted Alpha Therapies
U.S. STOCKS ON THE MOVE-Viridian, Carvana, Titan Machinery
U.S. STOCKS ON THE MOVE-3M Co, copper miners, Build-A-Bear Workshop
SVB Securities sees promise in Fusion Pharma's cancer therapy
Fusion Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Fusion Pharmaceuticals Announces Third Quarter Financial Results
Brief: Fusion Pharmaceuticals Appoints Dmitri Bobilev As Chief Medical Officer
Fusion Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Fusion Pharmaceuticals Doses First Patient In Phase 1/2 Study Of Advanced Solid Tumor Treatment
Fusion Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Fusion Pharmaceuticals reports Q2 results
Brief: Fusion Pharmaceuticals Inc Announces Second Quarter 2022 Financial Results
Brief: Fusion Announces U.S. FDA Clearance Of IND For FPI-2059